PSNL News and Press, Personalis Inc. From 01/05/24

2024-01-05 09:38:15 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis expects workforce reduction to extend cash runway into 2026 Cancer test developer Personalis to cut 65 jobs to reduce costs Seeking Alpha’s Qu...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue i...

2023-12-21 17:17:27 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis expects workforce reduction to extend cash runway into 2026 Cancer test developer Personalis to cut 65 jobs to reduce costs Seeking Alpha’s Qu...

2023-12-04 11:41:08 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Cancer test developer Personalis to cut 65 jobs to reduce costs Personalis to issue 9.2M shares as Tem...

Workforce restructuring and recent commercial collaboration help position company for long-term success Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staf...

2023-12-01 17:09:11 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Personalis to issue 9.2M shares as Tempus joins hands for cancer test Personalis GAAP EPS of -$0.60 mi...

2023-11-29 14:41:57 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Personalis GAAP EPS of -$0.60 misses by $0.08, revenue of $18.2M beats by $1.22M Personalis Q3 2023 Ea...

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc. , a leader in artificial intelligence and precision medicine, today announ...

2023-11-07 23:04:10 ET Personalis, Inc. (PSNL) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Re...

2023-11-07 16:04:47 ET More on Personalis Personalis: Collaborations Should Ignite Growth Narrative Personalis Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Personalis Historical earnings data for Personalis For further details see: ...